Search
for

    Glossary Ruxolitinib

    medication that inhibits JAK enzymes to treat certain diseases

    Ruxolitinib, also known by the brand name Jakafi, is a medication that inhibits Janus kinase (JAK) enzymes, which are involved in the signaling pathways that regulate immune function and blood cell production. It is primarily used to treat conditions like myelofibrosis and polycythemia vera, and has shown promise in treating certain types of alopecia by modulating the immune response that attacks hair follicles.

    Research 10 of 581

    1. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata JCI insight · 2016 · 196 citations
    2. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA) Journal of the American Academy of Dermatology · 2015 · 157 citations
    3. Ruxolitinib for the treatment of severe alopecia areata Journal of the American Academy of Dermatology · 2018 · 37 citations
    4. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease Blood · 2018 · 33 citations
    5. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring International Journal of Dermatology · 2017 · 25 citations
    6. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream Pharmaceutics · 2021 · 24 citations
    7. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient Skin appendage disorders · 2017 · 22 citations
    8. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib Acta Dermato Venereologica · 2020 · 13 citations
    9. Ruxolitinib found to cause eyelash growth: a case report Journal of medical case reports · 2017 · 9 citations
    10. Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective Dermatology practical & conceptual · 2022 · 8 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →